JP2002505676A5 - - Google Patents

Download PDF

Info

Publication number
JP2002505676A5
JP2002505676A5 JP1999503464A JP50346499A JP2002505676A5 JP 2002505676 A5 JP2002505676 A5 JP 2002505676A5 JP 1999503464 A JP1999503464 A JP 1999503464A JP 50346499 A JP50346499 A JP 50346499A JP 2002505676 A5 JP2002505676 A5 JP 2002505676A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1999503464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002505676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA1998/000603 external-priority patent/WO1998058633A2/en
Publication of JP2002505676A publication Critical patent/JP2002505676A/ja
Publication of JP2002505676A5 publication Critical patent/JP2002505676A5/ja
Pending legal-status Critical Current

Links

JP50346499A 1997-06-23 1998-06-22 微量投与療法 Pending JP2002505676A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5049197P 1997-06-23 1997-06-23
US60/050,491 1997-06-23
US8675098P 1998-05-27 1998-05-27
US60/086,750 1998-05-27
PCT/CA1998/000603 WO1998058633A2 (en) 1997-06-23 1998-06-22 Microdose therapy of vascular conditions by no donors

Publications (2)

Publication Number Publication Date
JP2002505676A JP2002505676A (ja) 2002-02-19
JP2002505676A5 true JP2002505676A5 (https=) 2005-12-22

Family

ID=26728335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50346499A Pending JP2002505676A (ja) 1997-06-23 1998-06-22 微量投与療法

Country Status (9)

Country Link
US (4) US6165975A (https=)
EP (1) EP0998274B1 (https=)
JP (1) JP2002505676A (https=)
AT (1) ATE315931T1 (https=)
AU (1) AU756136B2 (https=)
CA (1) CA2294480C (https=)
DE (1) DE69833254T2 (https=)
ES (1) ES2257813T3 (https=)
WO (1) WO1998058633A2 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6323211B1 (en) * 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
WO1998058633A2 (en) * 1997-06-23 1998-12-30 Queen's University At Kingston Microdose therapy of vascular conditions by no donors
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6056966A (en) * 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
US6436997B1 (en) * 1998-06-01 2002-08-20 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension
EP1235563A2 (en) 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
EP1175210A4 (en) 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc STRENGTHENING THE BIODAVAILABILITY OF DRUGS IN THE BRAIN
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
WO2001085013A2 (en) 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
KR20040052489A (ko) 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
WO2002074916A2 (en) * 2001-03-16 2002-09-26 Centocor, Inc. Reg-like protein immunoglobulin derived proteins, compositions, methods and uses
US6444237B1 (en) 2001-09-13 2002-09-03 Pamela A. Heleen Herbal composition for enhancing sexual response
FR2832634A1 (fr) * 2001-11-29 2003-05-30 Univ Pasteur Utilisation des isomeres l de derives aminoacides de l'hydroxyguanidine pour la production de no, compositions pharmaceutiques les contenant et utilisations pharmaceutiques
US20030158184A1 (en) * 2001-12-21 2003-08-21 Garvey David S. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU2003291037A1 (en) 2002-11-18 2004-06-15 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
JP4723476B2 (ja) * 2003-02-14 2011-07-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
US7491248B2 (en) 2003-09-25 2009-02-17 Afton Chemical Corporation Fuels compositions and methods for using same
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas
WO2005077405A1 (en) * 2004-02-06 2005-08-25 Cancer Treatment International Compositions and methods for the treatment of cancer by systemic elevation of lactate and consequent depletion of arginine
AU2005218539A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
SI1750766T1 (sl) 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20080193385A1 (en) * 2007-02-08 2008-08-14 Todd Maibach Compositions and methods for treating neuropathy
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CA2973096A1 (en) 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Angiogenic treatment of ischemic heart disease
AU2016220304B2 (en) * 2015-02-16 2019-07-25 Venturis Therapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681459A (en) * 1970-10-01 1972-08-01 Armour Pharma Guanidine compounds and use of same
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
JPS56133381A (en) 1980-03-25 1981-10-19 Nippon Kayaku Co Ltd Pressure-sensitive adhesive tape or sheet containing nitroglycerin
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4559222A (en) 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4751087A (en) 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4681584A (en) 1985-05-03 1987-07-21 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4655766A (en) 1985-08-01 1987-04-07 Alza Corporation Fluid imbibing pump with self-regulating skin patch
CA1272922A (en) 1986-06-03 1990-08-21 Peter William Berry Drug delivery device, its preparation and use
US5071656A (en) 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US5300291A (en) 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5284828A (en) * 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
WO1992013545A1 (en) * 1991-01-31 1992-08-20 Abbott Laboratories Endothelin converting enzyme inhibitors
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
DE4305881C1 (de) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5595970A (en) * 1993-07-16 1997-01-21 Schering Aktiengesellschaft Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5658936A (en) * 1995-09-18 1997-08-19 Brigham & Women's Hospital, Inc. Enhancement of erectile function with renin-angiotensin system inhibitors
US5688499A (en) * 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
US6306541B1 (en) 1996-06-11 2001-10-23 Dow Corning Corporation Electrodes for lithium ion batteries using polysilanes
GB2314771B (en) * 1996-07-02 2000-09-06 Multimed Ltd Topical preparation for relief of erectile dysfunction
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998058633A2 (en) * 1997-06-23 1998-12-30 Queen's University At Kingston Microdose therapy of vascular conditions by no donors
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1235563A2 (en) * 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction

Similar Documents

Publication Publication Date Title
JP2000509942A5 (https=)
JP2000510751A5 (https=)
JP2000507042A5 (https=)
JP2000509637A5 (https=)
JP2000509912A5 (https=)
JP2000509635A5 (https=)
JP2001500448A5 (https=)
JP2001517329A5 (https=)
JP2001513109A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2002505676A5 (https=)
JP2001527558A5 (https=)
JP2000510793A5 (https=)
JP2000508022A5 (https=)
JP2002500587A5 (https=)
JP2002504105A5 (https=)
JP2000516989A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2001508885A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)